Related Experiment Video
Updated: Sep 23, 2026
Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
Optimized Carbohydrate-Based Nanogel Formulation to Sensitize Hypoxic Tumors
Diana Diaz-Dussan1, Yi-Yang Peng1, Faisal Bin Rashed2
1Department of Chemical & Materials Engineering, University of Alberta, Edmonton T6G 1H9, Alberta, Canada.
Abstract:
Solid tumors are often poorly vascularized, which impairs oxygen supply and drug delivery to the cells. This often leads to genetic and translational adaptations that promote tumor progression, invasion, metastasis, and resistance to conventional chemo-/radiotherapy and immunotherapy. A hypoxia-directed nanosensitizer formulation of a hypoxia-activated prodrug (HAP) was developed by encapsulating iodoazomycin arabinofuranoside (IAZA), a 2-nitroimidazole nucleoside-based HAP, in a functionally modified carbohydrate-based nanogel, facilitating delivery and accrual selectively in the hypoxic head and neck and prostate cancer cells. Although IAZA has been reported as a clinically validated hypoxia diagnostic agent, recent studies have pointed to its promising hypoxia-selective anti-tumor properties, which make IAZA an excellent candidate for further exploration as a multimodal theranostic of hypoxic tumors. The nanogels are composed of a galactose-based shell with an inner core of thermoresponsive (di(ethylene glycol) methyl ethyl methacrylate) (DEGMA). Optimization of the nanogels led to high IAZA-loading capacity (≅80-88%) and a slow time-controlled release over 50 h. Furthermore, nanoIAZA (encapsulated IAZA) displayed superior in vitro hypoxia-selective cytotoxicity and radiosensitization in comparison to free IAZA in the head and neck (FaDu) and prostate (PC3) cancer cell lines. The acute systemic toxicity profile of the nanogel (NG1) was studied in immunocompromised mice, indicating no signs of toxicity. Additionally, growth inhibition of subcutaneous FaDu xenograft tumors was observed with nanoIAZA, demonstrating that this nanoformulation offers a significant improvement in tumor regression and overall survival compared to the control.
Insights
A novel nanogel effectively delivers a hypoxia-activated prodrug (HAP) to solid tumors, enhancing cancer cell killing and tumor regression with minimal toxicity. This hypoxia-directed therapy shows promise for treating resistant cancers.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Solid tumors often exhibit poor vascularization, leading to hypoxia.
- Tumor hypoxia promotes cancer progression, invasion, metastasis, and treatment resistance.
Purpose of the Study:
- To develop and evaluate a hypoxia-directed nanosensitizer for targeted cancer therapy.
- To encapsulate a hypoxia-activated prodrug (HAP) into a novel nanogel for improved delivery and efficacy.
Main Methods:
- A carbohydrate-based nanogel encapsulating iodoazomycin arabinofuranoside (IAZA), a HAP, was synthesized.
- The nanogel formulation (nanoIAZA) was characterized for loading capacity, release kinetics, and in vitro/in vivo efficacy.
- Cytotoxicity, radiosensitization, and systemic toxicity were assessed in cancer cell lines and mouse models.
Main Results:
- The nanogel achieved high IAZA loading (80-88%) with controlled release over 50 hours.
- nanoIAZA demonstrated superior in vitro hypoxia-selective cytotoxicity and radiosensitization compared to free IAZA.
- In vivo studies showed significant tumor growth inhibition and improved survival in FaDu xenografts with no observed toxicity.
Conclusions:
- The developed nanoIAZA formulation is a promising hypoxia-targeted theranostic agent.
- This nanosensitizer offers enhanced anti-tumor efficacy and improved tumor regression for hypoxic cancers.
- The nanogel platform facilitates selective drug delivery, overcoming limitations of conventional therapies.
